Abstract
ABSTRACT: The mdx mouse has been used for the development of cellular and gene therapies for Duchenne muscular dystrophy. The relatively frequent occurrence of dystrophin-positive muscle cells called revertants has hampered these efforts by interfering with data interpretation. The mdx4cv and mdx5cv dystrophin mouse mutants have approximately 10-fold fewer revertants than the mdx mutant at both 2 and 6 mo. The mdx3cv dystrophin mouse mutant may be a useful model for some types of human dystrophin deficiencies in which the levels of dystrophin are low but not completely absent.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Danko, I., Chapman, V. & Wolff, J. The Frequency of Revertants in mdx Mouse Genetic Models for Duchenne Muscular Dystrophy. Pediatr Res 32, 128–131 (1992). https://doi.org/10.1203/00006450-199207000-00025
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1203/00006450-199207000-00025
This article is cited by
-
What is the level of dystrophin expression required for effective therapy of Duchenne muscular dystrophy?
Journal of Muscle Research and Cell Motility (2019)
-
Proteomic profiling of liver tissue from the mdx-4cv mouse model of Duchenne muscular dystrophy
Clinical Proteomics (2018)
-
Humanizing the mdx mouse model of DMD: the long and the short of it
npj Regenerative Medicine (2018)
-
Loss of niche-satellite cell interactions in syndecan-3 null mice alters muscle progenitor cell homeostasis improving muscle regeneration
Skeletal Muscle (2016)
-
Elastase levels and activity are increased in dystrophic muscle and impair myoblast cell survival, proliferation and differentiation
Scientific Reports (2016)